84 related articles for article (PubMed ID: 20227681)
1. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
Levine SZ; Leucht S
Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
[TBL] [Abstract][Full Text] [Related]
2. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
Levine SZ; Rabinowitz J; Case M; Ascher-Svanum H
J Clin Psychopharmacol; 2010 Aug; 30(4):446-9. PubMed ID: 20631562
[TBL] [Abstract][Full Text] [Related]
3. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
4. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
6. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
7. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
Leucht S; Busch R; Hamann J; Kissling W; Kane JM
Biol Psychiatry; 2005 Jun; 57(12):1543-9. PubMed ID: 15953491
[TBL] [Abstract][Full Text] [Related]
8. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine in schizophrenia: onset of action within the first week of treatment.
Small JG; Kolar MC; Kellams JJ
Curr Med Res Opin; 2004 Jul; 20(7):1017-23. PubMed ID: 15265246
[TBL] [Abstract][Full Text] [Related]
11. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.
Levine SZ; Rabinowitz J; Faries D; Lawson AH; Ascher-Svanum H
Schizophr Res; 2012 May; 137(1-3):141-6. PubMed ID: 22316567
[TBL] [Abstract][Full Text] [Related]
12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
14. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
15. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
16. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Levine SZ; Leucht S
Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
[TBL] [Abstract][Full Text] [Related]
17. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
18. Comparative remission rates of schizophrenic patients using various remission criteria.
Beitinger R; Lin J; Kissling W; Leucht S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1643-51. PubMed ID: 18616969
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]